COVID-19 and Its Implications for Thrombosis and Anticoagulation

Area of Science:

• Hematology
• Infectious Diseases
• Critical Care Medicine

Background:

• COVID-19 (novel coronavirus disease 2019) is associated with a unique coagulopathy.
• This coagulopathy presents with diverse thrombotic events, including venous thromboembolism, catheter occlusion, and ischemic strokes, even with anticoagulation.
• Hospitalized COVID-19 patients often require anticoagulation, but optimal strategies remain debated.

Purpose of the Study:

• To critically evaluate current evidence regarding anticoagulation in hospitalized COVID-19 patients.
• To address key questions on anticoagulation dosage escalation, monitoring, and post-discharge management.
• To explore the role of antiphospholipid antibodies and the significance of specific thrombotic events in COVID-19 coagulopathy.

Main Methods:

• Systematic review and interpretation of available clinical data and evidence.
• Analysis of studies investigating prophylactic, intermediate, and full-dose anticoagulation.
• Examination of literature on anticoagulation monitoring and post-discharge treatment strategies.

Main Results:

• Hospitalized COVID-19 patients benefit from prophylactic anticoagulation.
• Evidence supports considering intermediate or full-dose anticoagulation in select high-risk patients.
• Antiphospholipid antibodies may play a role in some COVID-19 thrombotic events.

Conclusions:

• Optimizing anticoagulation in COVID-19 requires careful patient selection and risk stratification.
• Further research is needed to establish definitive guidelines for anticoagulation monitoring and duration.
• Understanding the interplay between COVID-19 coagulopathy and specific thrombotic manifestations is crucial for patient management.